Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19

Open data API in a single place

Provided by Kungliga Tekniska högskolan

Get early access to Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19 API!

Let us know and we will figure it out for you.

Dataset information

Country of origin
Updated
2024.07.22 00:00
Created
2024.07.22
Available languages
English
Keywords
Humoural immunology and immunochemistry, Proteomics and metabolomics, Autoimmunity
Quality scoring

Dataset description

Note: The DOI of the related paper will be provided upon publication. These datasets contain information on autoantibody and anti-SARS-CoV-2 IgG levels. In this study, 478 healthcare workers and 48 patients were followed prospectively over 5 visits from May 2020 to Sept 2021. SARS-CoV-2 serology and autoantibodies were assessed using planar and bead-based arrays. Detected epitopes were validated in blood and cerebrospinal fluid from two independent cohorts of Neuro-COVID patients (n=25) and pre-pandemic healthy controls (n=29). The datasets contain: - SARS-CoV-2 serological profiles measured in all samples (above) using 3-plex bead arrays. The data is reported as raw and normalized MFI (AU) and compound serostatus. - Proteome-wide autoantibody profiles measured in 12 sample pools using planar arrays. The data is reported as median fluorescent intensity, in raw and normalized arbitrary units (MFI [AU]), and reactivity classification. - Targeted autoantibody profiles measured in 478 healthcare workers and 48 patients across 5 time points using 363-plex bead arrays. The data is reported as raw and normalized MFI (AU), fold change (FC) across infection, and new-onset classification. - Peptide epitope mapping autoantibody profiles measured in a 142 healthcare workers and COVID-19 patients across 2 time points, and all Neuro-COVID patients (n=25) and pre-pandemic healthy controls (n=29), using 93-plex bead arrays. The data is reported as raw and normalized MFI (AU), and fold change (FC) across infection. Source data is provided with the paper. Access to this individual-level human data can be granted for non-commercial validation purposes and upon reasonable request to the provided contact. A reasonable request should contain the following: - Name of PI and host organization - Contact details - The scientific purpose of the data access request - Commitment to inform when the data has been used in a publication - Commitment not to host or share the data outside the requesting organization - Statement of non-commercial use of data
European data infrastructure with broad catalog discovery, free evaluation access and production-grade API options.
190K+
indexed dataset pages
32
countries and EU institutions
2019
API-first since
Free API quota
for evaluation and prototypes
SLA
history and push on production APIs
FAQ

Questions before production use

Practical answers on evaluation, licensing, freshness, versioning and support.

api.store is built and operated by Apitalks s.r.o. Company details and a direct contact path are linked in the footer for vendor checks and procurement review.
Yes. Selected APIs include a free API quota, so your team can validate coverage, freshness, response shape and workflow fit before asking for a production plan.
Often yes, but usage rights depend on the source license and dataset. We surface source, license and update metadata where available, and can help review terms before a production integration.
Maintained APIs include update metadata where available. For production integrations, we can add history, monitoring and push updates so changes are easier to detect and act on.
Production APIs can add SLA, stable identifiers, versioning support, history, push updates and direct support around the data your product or AI workflow depends on.

Didn't find the API you need?

Let us know and we will figure it out for you.

European data discovery with free evaluation access and production-grade API options.

Copyright © 2026. Made by Apitalks